Kwiinyanga ezilithoba emva kokwaziswa kwayo e-US, i-Eisai kunye ne-Biogen's Alzheimer's Alzheimer's Leqembi is ukudibana ukuxhathisa okubonakalayo ekukhuleni kwayo okuxhaphakileyo, ubukhulu becala ngenxa yokuthandabuza phakathi kwabanye oogqirha malunga nokusebenza kokunyanga esi sifo sobuchopho siwohlokayo.
Ngaphandle kokuba lichiza lokuqala elingqinwe ukuba licothisa ukuqhubeka kwe-Alzheimer's, amathandabuzo aqiniweyo phakathi kwababoneleli bezempilo malunga nexabiso lokunyanga le meko abonakala engumqobo omkhulu.
Iingcali ze-Alzheimer ekuqaleni bezilindele imingeni enxulumene neprotocol efunwa nguLeqembi, ebandakanya uvavanyo olongezelelweyo lokuxilonga, ukufakwa kabini ngenyanga, kunye nokujongwa rhoqo kwengqondo ukujonga iziphumo ezibi ezinokuthi zibe mbi. Ngokwenene, ezi mfuno zibe negalelo ekuthatheni ichiza kancinane ukusukela ekuvunyweni kwalo yi-US Food and Drug Administration, njengoko kungqinwa ziingxoxo neengcali zemithambo-luvo ezingama-20 kunye noogqirha bezifo kwimimandla eyahlukeneyo yase-US.
Ngokutsho kweReuters, oogqirha abasixhenxe badize ukuthandabuza kwabo ukumisela iLeqembi, bekhankanya amathandabuzo malunga nokusebenza kweli chiza, ixabiso lalo, kunye neengozi ezinxulumene nalo. Ngaphezu koko, iqela leengcaphephe ezintandathu ezikhokelayo kwicandelo libonise ukuba "i-nihilism yonyango" - imbono yokuba i-Alzheimer's yimeko engenakunqotshwa - ineempembelelo ezibaluleke kakhulu kunokuba bekulindelwe ekunciphiseni intshiseko phakathi koogqirha bokhathalelo lokuqala, oogqirha bezonyango, kunye neengcali zemithambo-luvo. Oku kuthandabuza kuchaphazela ukuvuma kwabo ukuthumela izigulane kwiingcali zokukhumbula ukuze bafumane unyango olunokubakho kunye noLeqembi.
Ezinye iingcali zithi ukungafuni phakathi kwabanye oogqirha kunokuvela kwixesha elide lamathandabuzo eliye lavala ukusebenza kokujolisa kwi-Alzheimer's protein beta amyloid ukucothisa ukuqhubeka kwesi sifo. Ngaphambi kweziphumo ezikhuthazayo zolingo lweLeqembi, abaninzi kwinkalo yezonyango balujonga olu khokelo lophando lungenasiqhamo.
Ukukhathazeka kuye kwaphakanyiswa ngabanye abaqeqeshi bezonyango malunga nemiphumo emibi yeLeqembi, njengokuvuvukala kwengqondo kunye nokuphuma kwegazi, ngaphezu kweendleko ezibandakanyekayo kunye ne-$ 26,500 yexabiso lonyaka, i-MRIs rhoqo, kunye ne-infusions kabini ngenyanga.
I-Leqembi yaba lichiza lokuqala elijolise kwi-amyloid ukufumana imvume epheleleyo ye-FDA emva kokubonisa ukwehla kwe-27% ekunciphiseni kwengqondo phakathi kwezigulane ze-Alzheimer ezikwinqanaba lokuqala ngexesha lolingo lwezonyango. Ngaphandle kwenjongo yokuqala yokunyanga abantu baseMelika abayi-10,000 ekupheleni kuka-Matshi, ngamawaka ambalwa kuphela aye aqalisa unyango ekupheleni kukaJanuwari, njengoko kuxelwe ngu-Eisai, osisithethi sakhe salile ukunika amanani ahlaziyiweyo.
Ukwamkelwa kwamachiza amatsha, nalawo angafuni tshintsho lubalulekileyo kunyango, kucotha ngendlela engathethekiyo. Uphando lubonise ukuba kunokuthatha umndilili weminyaka eli-17 ukuba uphando lwezonyango lube yinto yesiqhelo. I-Alzheimer's ichaphazela abantu baseMelika abangaphezu kwezigidi ezi-6, kodwa ngaphantsi kwesiqingatha se-neurologists e-US bacebisa i-Leqembi kwizigulane zabo, ngokophando lukaJanuwari ngobomi. isayensi umphandi wemarike Spherix Global Insights.
Ibhalwe ngu Alius Noreika
